This rally is still in its middle innings and there's a lot more bull left to play, Jim Cramer told his Mad Money viewers Wednesday, but real, roaring, rip-snorting bull markets are different than ordinary markets, so we need a new set of rules.
The first rule of a bull market? Rethink your discipline. In a normal market, when you have decent gains, you sell a little. But in a bull market, hold onto those gains a little longer or you'll likely miss even more upside.
Rule No 2: The analysts matter. Main Street has shunned analysts for years, but in a bull market, when an analyst says to buy, it matters.
Cramer's third rule was that there's nothing more powerful than momentum. Stocks that are already up big can still go higher as investors pile in. Respect the momentum.
Along those same lines is rule No. 4: Accept the anointed ones. Those stocks that everyone is talking about today will likely be the same stocks they're still talking about tomorrow and next week.
Rule No. 5: Ignore the negative news. The markets aren't paying attention to Washington or tax reforms, it only cares about what's working.
Don't think about valuations was Cramer's sixth rule. In a bull market, valuations are relative and the whole market will move together.
Finally, rule No. 7: Not all stocks are good stocks. The food and drug sector, for example, remains a horrible place to be. That's why you must continue to stay diversified and avoid stocks that have moved too far, too fast.
On Real Money, Cramer says the whole tech sector needs a pullback. "It's been a little crazed." Get more on his insights with a free trial subscription to Real Money.
Executive Decision: Allergan
For his "Executive Decision" segment, Cramer sat down with Brent Saunders, chairman, president and CEO of drugmaker Allergan (AGN - Get Report) , an Action Alerts PLUS holding that just posted a four-cents-a-share earnings beat on sales that rose 11.4% year-over-year.
Saunders explained that the company's core portfolio of drugs remains strong and it continues to cultivate durable assets that will perform over the long term. He said the loss of exclusivity on some of Allergan's drugs is all part of their business, and management gets paid to work through these events.
Saunders continued by saying that the pipeline of new drugs also remains strong, with six drugs in Phase III testing. He was also bullish on his company's CoolScuplting procedure, which just past five million treatments.
Saunders ended by saying that Allergan believes both in protecting their intellectual property and having exclusivity with their drugs for taking risks, but also in pricing their those drugs responsibly.
Cramer reiterated his recommendation of Allergan.
Cramer and the AAP team are looking at the Fed statement (no surprise there) and the outlook for oil. Find out what they're telling their investment club members and get in on the conversation with a free trial subscription to Action Alerts PLUS.
Leggo That Eggo?
Cramer said the analysts are reaching for something, anything, to like in the food space, and Kellogg -- with its 3% yield and a future that looks slightly better than the past -- seems to be all it takes in this market.
But as Cramer noted, cereal is expensive, and just because Kellogg has raised prices, it doesn't seem to have raised the value in the eyes of the consumer. And let's face it: Eggo, Pringles and Cheez-it are not the healthiest of brands. These products were invented for convenience, and in today's natural and organic-hungry market, convenience is not as high on the priority list.
Executive Decision: Tyson Foods
Hayes said that Tyson believes that it needs to be part of the solution when it comes to feeding the world's growing population, and the company remains committed to being sustainable. Despite being our nation's largest producer of chicken, it has gone antibiotic-free and plans on staying that way.
Tyson processes more than 35 million chickens each week and Hayes said that level of production just can't be met by local backyard farms.
While Hayes admitted that the food business is being disrupted by companies like Amazon (AMZN - Get Report) , he said protein is not a fad and consumers around the globe want more of it. Nearly 10% of Tyson's sales come from exports and there's "more to come," according to Hayes.
Cramer said while he doesn't like the food category, he does like Tyson Foods.
In the Lightning Round, Cramer was bullish on Intuitive Surgical (ISRG - Get Report) , Chicago Mercantile Exchange (CME - Get Report) , American Express (AXP - Get Report) , Mastercard (MA - Get Report) , Visa (V - Get Report) , PayPal (PYPL - Get Report) and United Rentals (URI - Get Report) .
Executive Decision: Cypress Semiconductor
For his final "Executive Decision" segment, Cramer also spoke with Hassane El-Khoury, president and CEO of Cypress Semiconductor (CY - Get Report) , a stock that's up a quick 17% since Cramer last checked in back in August, and 36% for the year.
El-Khoury started off by saying that Cypress is the No. 1 chipmaker for wireless connectivity and device makers are flocking to the leader. Whether you're talking homes, cars or widgets, if your devices needs wifi or bluetooth connectivity, you need chips from Cypress.
El-Khoury noted that the company's Internet of things business is up an astounding 80% year-over-year and he has full confidence in the ability to execute its growth plans.
Automotive is another exciting area for the company. El-Khoury said that Cypress is inside most cars today and it has a 65% market share in autonomous driving platforms.
Cramer said that Cypress remains an inexpensive stock.
Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.
More of What's Trending on TheStreet: